476 related articles for article (PubMed ID: 26170630)
21. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
Zhang L; Li S; Zhang Y; Zhan J; Zou BY; Smith R; Martin PD; Jiang Y; Liao H; Guan Z
Clin Ther; 2011 Mar; 33(3):315-27. PubMed ID: 21600385
[TBL] [Abstract][Full Text] [Related]
22. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
Dadu R; Hu MN; Grubbs EG; Gagel RF
Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
[TBL] [Abstract][Full Text] [Related]
23. Systemic treatment and management approaches for medullary thyroid cancer.
Ernani V; Kumar M; Chen AY; Owonikoko TK
Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
[TBL] [Abstract][Full Text] [Related]
24. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Wells SA; Robinson BG; Gagel RF; Dralle H; Fagin JA; Santoro M; Baudin E; Elisei R; Jarzab B; Vasselli JR; Read J; Langmuir P; Ryan AJ; Schlumberger MJ
J Clin Oncol; 2012 Jan; 30(2):134-41. PubMed ID: 22025146
[TBL] [Abstract][Full Text] [Related]
25. Vandetanib: first global approval.
Commander H; Whiteside G; Perry C
Drugs; 2011 Jul; 71(10):1355-65. PubMed ID: 21770481
[TBL] [Abstract][Full Text] [Related]
26. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
27. Vandetanib for the treatment of thyroid cancer.
Langmuir PB; Yver A
Clin Pharmacol Ther; 2012 Jan; 91(1):71-80. PubMed ID: 22158569
[TBL] [Abstract][Full Text] [Related]
28. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
[TBL] [Abstract][Full Text] [Related]
29. Transcriptional targeting of oncogene addiction in medullary thyroid cancer.
Valenciaga A; Saji M; Yu L; Zhang X; Bumrah C; Yilmaz AS; Knippler CM; Miles W; Giordano TJ; Cote GJ; Ringel MD
JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135308
[TBL] [Abstract][Full Text] [Related]
30. Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation.
Paepegaey AC; Cochand-Priollet B; Louiset E; Sarfati PO; Alifano M; Burnichon N; Bienvenu-Perrard M; Lahlou N; Bricaire L; Groussin L
Thyroid; 2017 Apr; 27(4):587-590. PubMed ID: 28068878
[TBL] [Abstract][Full Text] [Related]
31. Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.
Hatem R; Labiod D; Château-Joubert S; de Plater L; El Botty R; Vacher S; Bonin F; Servely JL; Dieras V; Bièche I; Marangoni E
Int J Cancer; 2016 May; 138(10):2510-21. PubMed ID: 26686064
[TBL] [Abstract][Full Text] [Related]
32. YAP confers resistance to vandetanib in medullary thyroid cancer.
Wang H; Tang J; Su Z
Biochem Cell Biol; 2020 Jun; 98(3):443-448. PubMed ID: 32449862
[TBL] [Abstract][Full Text] [Related]
33. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
Lam ET; Ringel MD; Kloos RT; Prior TW; Knopp MV; Liang J; Sammet S; Hall NC; Wakely PE; Vasko VV; Saji M; Snyder PJ; Wei L; Arbogast D; Collamore M; Wright JJ; Moley JF; Villalona-Calero MA; Shah MH
J Clin Oncol; 2010 May; 28(14):2323-30. PubMed ID: 20368568
[TBL] [Abstract][Full Text] [Related]
34. Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.
Oba T; Chino T; Soma A; Shimizu T; Ono M; Ito T; Kanai T; Maeno K; Ito KI
Endocr J; 2020 Dec; 67(12):1215-1226. PubMed ID: 32814730
[TBL] [Abstract][Full Text] [Related]
35. Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer.
Brassard M; Neraud B; Trabado S; Salenave S; Brailly-Tabard S; Borget I; Baudin E; Leboulleux S; Chanson P; Schlumberger M; Young J
J Clin Endocrinol Metab; 2011 Sep; 96(9):2741-9. PubMed ID: 21715537
[TBL] [Abstract][Full Text] [Related]
36. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH
J Clin Oncol; 2017 Oct; 35(29):3315-3321. PubMed ID: 28817373
[TBL] [Abstract][Full Text] [Related]
37. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
Fox E; Widemann BC; Chuk MK; Marcus L; Aikin A; Whitcomb PO; Merino MJ; Lodish M; Dombi E; Steinberg SM; Wells SA; Balis FM
Clin Cancer Res; 2013 Aug; 19(15):4239-48. PubMed ID: 23766359
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.
Hu MI; Elisei R; Dedecjus M; Popovtzer A; Druce M; Kapiteijn E; Pacini F; Locati L; Krajewska J; Weiss R; Gagel RF
Endocr Relat Cancer; 2019 Feb; 26(2):241-250. PubMed ID: 30557850
[TBL] [Abstract][Full Text] [Related]
39. Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients.
Tiedje V; Ting S; Walter RF; Herold T; Worm K; Badziong J; Zwanziger D; Schmid KW; Führer D
Eur J Endocrinol; 2016 Sep; 175(3):173-80. PubMed ID: 27283290
[TBL] [Abstract][Full Text] [Related]
40. Vandetanib for the treatment of medullary thyroid carcinoma.
Cooper MR; Yi SY; Alghamdi W; Shaheen DJ; Steinberg M
Ann Pharmacother; 2014 Mar; 48(3):387-94. PubMed ID: 24259657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]